SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-015868
Filing Date
2021-08-05
Accepted
2021-08-05 16:17:25
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngm-20210805.htm   iXBRL 8-K 37865
2 EX-99.1 ngm-20210805xexx991.htm EX-99.1 90925
6 GRAPHIC a2.jpg GRAPHIC 21732
  Complete submission text file 0001628280-21-015868.txt   312637

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20210805.xsd EX-101.SCH 1893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20210805_lab.xml EX-101.LAB 24975
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20210805_pre.xml EX-101.PRE 13174
7 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20210805_htm.xml XML 11769
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 211148442
SIC: 2834 Pharmaceutical Preparations